Search clinical trials for: Sunitinib, Pemetrexed

Total 1533 results

Pfizer

Completed

A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies

Neoplasm, Malignant

Japan
Pfizer

Completed

A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors

Neoplasms

Canada, United States
University Health Network, Toronto
Pfizer

Completed

Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma (SNIPP)

Pheochromocytoma | Paraganglioma

Canada, Netherlands
The First Affiliated Hospital of Guangzhou Medical...

Unknown

Pemetrexed Plus Oxaliplatin as Adjuvant Chemotherapy for Radically Resected Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
National Cancer Institute (NCI)

Completed

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
Patrick Joseph Loehrer Sr.

Completed

Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma

Thymic Carcinoma | Thymoma

United States
AGO Study Group
Philipps University Marburg Medical Center; HSK Reasearch GmbH Wiesbaden

Completed

Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor

Platinum Refractory Epithelial Ovarian Cancer | Primary Cancer of the Peritoneum | Cancer of the Fallopian Tube

Germany
Mothaffar Rimawi

Terminated

CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer (CRIZENT)

Breast Cancer

United States
Cogent Biosciences, Inc.

Recruiting

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Metastatic Cancer | Advanced Gastrointestinal Stromal Tumors

United States, Korea, Republic of, Spain, United Kingdom, Australia, France, Italy, Netherlands, Taiwan, Germany, Denmark, Hong Kong, Canada, Sweden, Norway, Mexico, Czechia, Argentina, Hungary, Brazil, Chile, Poland
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery

Kidney Cancer

United States
Pfizer

Completed

Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer

Breast Neoplasms

United States
Boehringer Ingelheim

Terminated

BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Japan
Pfizer

Completed

A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumors

United States, Czechia, France
Asan Medical Center

Completed

Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)

Metastatic Renal Cell Carcinoma

Korea, Republic of
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Relapsed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Pfizer

Completed

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene

Gastrointestinal Stromal Tumors

Korea, Republic of
California Pacific Medical Center Research Institute
Pfizer; University of California, San Francisco

Completed

Clinical Trial of Sutent to Treat Metastatic Melanoma

Metastatic Melanoma

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes

Canada, United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma

Canada
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery

Cervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Recurrent Cervical Cancer | Stage IVB Cervical Cancer | Cervical Adenosquamous Cell Carcinoma

Canada
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIC Fallopian Tube Cancer and other conditions

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Exelixis

Active, not recruiting

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Malignant Neoplasms of Urinary Tract | Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3... and other conditions

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus

Recurrent Uterine Sarcoma | Uterine Leiomyosarcoma

United States
Case Comprehensive Cancer Center

Completed

Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
University of Washington
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Cancer | Thyroid Gland Medullary Carcinoma | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid Cancer

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Adult Diffuse Large Cell Lymphoma

Canada
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Uterine Carcinosarcoma | Recurrent Uterine Corpus Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Stage IVA Uterine Corpus Cancer AJCC v7 | Stage IVB Uterine Corpus Cancer AJCC v7 | Uterine Corpus Carcinosarcoma

United States, Canada
Assistance Publique - Hôpitaux de Paris
Pfizer

Completed

Clinical Trial to Assess the Importance of Nephrectomy (CARMENA)

Metastatic Renal Cell Carcinoma

France
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Recurrent Malignant Gliomas

Adult Anaplastic Astrocytoma | Adult Diffuse Astrocytoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Oligodendroglioma | Adult Pineal Gland Astrocytoma

United States
Yamagata University

Unknown

Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma (CROSS-J-RCC)

Metastatic Renal Cell Carcinoma

Japan
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Bioequivalence Study of Sunitinib Malate Capsules.

Renal Cell Carcinoma | Gastrointestinal Stromal Tumors | Pancreatic Neuroendocrine Tumor

China
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)

Withdrawn

Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma

Classic Kaposi Sarcoma | AIDS-related Kaposi Sarcoma
Pfizer

Completed

Sutent Rechallenge In mRCC Patients (RESUME)

Metastatic Renal Cell Carcinoma

France
Pfizer

Terminated

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine

Breast Neoplasms

Australia, Canada, Bulgaria, Spain, Germany, Italy, Korea, Republic of, Turkey, Brazil, Colombia, Taiwan, Philippines, Singapore, Mexico, United Kingdom, Hong Kong, India, South Africa, Japan, France, Argentina, Chile, Peru
Shanghai Shengdi Pharmaceutical Co., Ltd

Not yet recruiting

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Non-squamous Non-small Cell Lung Cancer

China
Fundacion para la Investigacion Biomedica del Hospital...

Completed

To Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of Sunitinib

Cancer

Spain
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer

Fatigue | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
Icahn School of Medicine at Mount Sinai
Pfizer

Completed

Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer

Cancer

United States
Northwestern University
National Cancer Institute (NCI)

Unknown

Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases

Lymphoma | Brain and Central Nervous System Tumors | Metastatic Cancer

United States
Rongjie Tao
National Natural Science Foundation of China

Unknown

High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases

Brain Metastases

China
National Cancer Institute (NCI)
NRG Oncology

Completed

Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer

Recurrent Ovarian Carcinoma | Ovarian Clear Cell Adenocarcinoma

United States, Korea, Republic of
Pfizer

Completed

Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)

Carcinoma, Renal Cell

United States
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

Recurrent Childhood Ependymoma | Childhood Infratentorial Ependymoma | Childhood Supratentorial Ependymoma | Recurrent Childhood Cerebellar Astrocytoma | Recurrent Childhood Cerebral Astrocytoma | Recurrent Childhood Subependymal Giant Cell Astrocytoma | Childhood Mixed Glioma | Childhood Oligodendroglioma and other conditions

United States, Canada, Australia
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Pfizer

Terminated

Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung

United States, Germany, Italy
Sidney Kimmel Cancer Center at Thomas Jefferson...
Pfizer

Active, not recruiting

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage IIIC Intraocular Melanoma | Stage I Intraocular Melanoma | Stage IIA Intraocular Melanoma | Stage IIB Intraocular... and other conditions

United States
Beijing Konruns Pharmaceutical Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Completed

Kanitinib in Treating Patients With Advanced Solid Tumors

Solid Tumors

China
Ain Shams University

Unknown

Four Versus Six Cycles of Pemetrexed/Platinum for MPM

Malignant Pleural Mesothelioma

Egypt

Search clinical trials for: Sunitinib, Pemetrexed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations